582 related articles for article (PubMed ID: 25897019)
21. Evaluation of persistence, retention "rate" and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis.
Valcuende-Rosique A; Borrás-Blasco J; Martínez-Badal S; Cortes X; Aparicio-Rubio C; Casterá-Melchor E
Farm Hosp; 2022 Jun; 46(5):296-300. PubMed ID: 36183230
[TBL] [Abstract][Full Text] [Related]
22. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
23. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
24. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S; Mazor Y; Yanai H; Ron Y; Kopylov U; Yavzori M; Picard O; Fudim E; Maor Y; Lahat A; Coscas D; Eliakim R; Dotan I; Chowers Y
Aliment Pharmacol Ther; 2012 Mar; 35(6):714-22. PubMed ID: 22288419
[TBL] [Abstract][Full Text] [Related]
25. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.
Pisupati K; Tian Y; Okbazghi S; Benet A; Ackermann R; Ford M; Saveliev S; Hosfield CM; Urh M; Carlson E; Becker C; Tolbert TJ; Schwendeman SP; Ruotolo BT; Schwendeman A
Anal Chem; 2017 May; 89(9):4838-4846. PubMed ID: 28365979
[TBL] [Abstract][Full Text] [Related]
26. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
[TBL] [Abstract][Full Text] [Related]
27. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
[TBL] [Abstract][Full Text] [Related]
28. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
29. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
30. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
31. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.
Goncalves J; Myung G; Park M; Jeong D; Ghil J
Therap Adv Gastroenterol; 2019; 12():1756284819891081. PubMed ID: 31839806
[TBL] [Abstract][Full Text] [Related]
32. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade
Xue L; van Bilsen K; Schreurs MWJ; van Velthoven MEJ; Missotten TO; Thiadens AAHJ; Kuijpers RWAM; van Biezen P; Dalm VASH; van Laar JAM; Hermans MAW; Dik WA; van Daele PLA; van Hagen PM
Front Med (Lausanne); 2020; 7():418. PubMed ID: 32850911
[No Abstract] [Full Text] [Related]
33. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
34. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
35. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
Layegh Z; Ruwaard J; Hebing RCF; L' Ami MJ; van der Weele W; Nurmohamed MT; Krieckaert C; Wolbink G
Int J Rheum Dis; 2019 May; 22(5):869-873. PubMed ID: 30767391
[TBL] [Abstract][Full Text] [Related]
36. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
Parigi TL; D'Amico F; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2021 Jan; 21(1):37-46. PubMed ID: 32799561
[TBL] [Abstract][Full Text] [Related]
37. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
38. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
39. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
[TBL] [Abstract][Full Text] [Related]
40. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]